U.S. sets policy to seize patents of government-funded drugs if price deemed too high
Drug patent seizures are back on the table for the first time in over 40 years, with the Biden administration releasing a draft roadmap that explicitly lets the federal government license out medicines to competitors when companies charge prices most Americans can’t afford. The power has existed since 1980 but was never used or even defined — until now. Price itself is now a factor: if a drug was built on taxpayer-funded research through agencies like the NIH, and the company sells it out of reach of ordinary patients, generics could be authorized. Even as a credible threat, this reframes who publicly funded science is really for — and could shift drug pricing fights well beyond U.S. borders.









